FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386784286> ?p ?o ?g. }

• W4386784286 endingPage "072" @default.
• W4386784286 startingPage "PO" @default.
• W4386784286 abstract "Abstract Background: We hypothesized that radioactive iodine (RAI) can enhance the presentation of thyroid cancer immunogenic self- and neo-antigens to enhance the clinical benefit of immune checkpoint inhibitors (ICI). We conducted a phase 1 trial of RAI in combination with durvalumab (durva; anti-PD-L1) in patients (pts) with recurrent/metastatic (R/M) thyroid cancer. We report updated clinical outcomes and biological correlates performed on trial samples. Methods: Pts were required to have RECIST measurable R/M thyroid cancer with either &gt;1 RAI-avid tumor(s) on the most recent RAI scan or one tumor with SUVmax &lt;10 on FDG-PET. Prior therapies were allowed. Pts received durva 1500 mg IV every 4 weeks in combination with recombinant human TSH (rhTSH)-stimulated RAI (100 mCi) administered during cycle 1. Primary endpoint was safety and secondary endpoints included progression-free survival (PFS), defined as time from first durva dose until progression (PD) or death of any cause. Pre-treatment and on-treatment biopsies of the same target lesion were obtained from enrolled pts if feasible. Bulk RNA sequencing (RNAseq) was performed to assess transcriptomic characteristics of key tumor immune profiles and their correlation to PFS. Results: 11 pts enrolled; 7 pts underwent tumor biopsies. No dose-limiting toxicities or grade ≥3 adverse events related to drug were observed. BOR was 2 pts with partial responses, 7 pts with stable disease, and 2 pts with PD. Median PFS was 9.8 months with all patients eventually having PD events. Four pts had durable PFS &gt;12 months. RNAseq analysis was performed on the tumor biopsies. Linear correlation analysis of transcriptome data from on-treatment tumors demonstrated a strong association between PFS and transcriptional scores for HLA expression (R2=0.76), MHC class I expression (R2=0.74), and NK/T cell cytolytic activity (CYT) (R2=0.69). The on-treatment tumors from pts with PFS &gt;12 months had higher interferon-gamma (IFN-γ), HLA, MHC class I and CYT scores than pts with PFS&lt;12 months (p&lt;0.01). Baseline PD-L1 expression (normalized transcripts per million) was also significantly higher in pts with PFS&gt;12 months (p=0.02). Detectable anti-TG and/or elevated anti-TPO (&gt;1 IU/mL) autoantibody levels in pre-treatment serum samples (n=10) correlated with longer PFS on study treatment (p&lt;0.03). RNAseq gene set enrichment analysis (GSEA) of on- vs pre-treatment samples showed durva-RAI increased thyroid autoimmunity gene sets in addition to the induction of IFN-γ and antigen presentation pathway. Conclusions: Durva-RAI has a favorable safety profile and is associated with prolonged PFS (&gt;12 months) in a subset of pts with R/M thyroid cancer. Transcriptomic profiling reveals that durva-RAI enhancement of tumor antigen presentation and inflammation with T cell activation correlates to prolonged disease control. Enhancing pre-existing, subclinical autoimmunity against thyroid self-antigens may contribute to ICI efficacy. Further studies are needed to evaluate these hypotheses, including how RAI may contribute to ICI efficacy. Citation Format: Antoine Desilets, Winston Wong, Gnana P. Krishnamoorthy, Eric Jeffrey Sherman, Lara Dunn, Anuja Kriplani, James Vincent Fetten, Loren S. Michel, Erin McDonald, Ravinder K. Grewal, Mona Sabra, Laura Boucai, Stephanie Fish, Sofia Haque, Irina Ostrovnaya, Ronald A. Ghossein, James A. Fagin, David G. Pfister, Alan Loh Ho. Durvalumab in combination with radioactive iodine in recurrent/metastatic thyroid cancers: Update on clinical and correlative analyses [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-072." @default.
• W4386784286 created "2023-09-16" @default.
• W4386784286 creator A5005775817 @default.
• W4386784286 creator A5011145876 @default.
• W4386784286 creator A5015522959 @default.
• W4386784286 creator A5023390457 @default.
• W4386784286 creator A5024691456 @default.
• W4386784286 creator A5026148495 @default.
• W4386784286 creator A5036148408 @default.
• W4386784286 creator A5036572642 @default.
• W4386784286 creator A5037706189 @default.
• W4386784286 creator A5039982412 @default.
• W4386784286 creator A5041586147 @default.
• W4386784286 creator A5052154004 @default.
• W4386784286 creator A5053307625 @default.
• W4386784286 creator A5060512446 @default.
• W4386784286 creator A5061365371 @default.
• W4386784286 creator A5071357841 @default.
• W4386784286 creator A5080716045 @default.
• W4386784286 creator A5087689377 @default.
• W4386784286 creator A5089200597 @default.
• W4386784286 date "2023-09-15" @default.
• W4386784286 modified "2023-09-26" @default.
• W4386784286 title "Abstract PO-072: Durvalumab in combination with radioactive iodine in recurrent/metastatic thyroid cancers: Update on clinical and correlative analyses" @default.
• W4386784286 doi "https://doi.org/10.1158/1557-3265.aacrahns23-po-072" @default.
• W4386784286 hasPublicationYear "2023" @default.
• W4386784286 type Work @default.
• W4386784286 citedByCount "0" @default.
• W4386784286 crossrefType "journal-article" @default.
• W4386784286 hasAuthorship W4386784286A5005775817 @default.
• W4386784286 hasAuthorship W4386784286A5011145876 @default.
• W4386784286 hasAuthorship W4386784286A5015522959 @default.
• W4386784286 hasAuthorship W4386784286A5023390457 @default.
• W4386784286 hasAuthorship W4386784286A5024691456 @default.
• W4386784286 hasAuthorship W4386784286A5026148495 @default.
• W4386784286 hasAuthorship W4386784286A5036148408 @default.
• W4386784286 hasAuthorship W4386784286A5036572642 @default.
• W4386784286 hasAuthorship W4386784286A5037706189 @default.
• W4386784286 hasAuthorship W4386784286A5039982412 @default.
• W4386784286 hasAuthorship W4386784286A5041586147 @default.
• W4386784286 hasAuthorship W4386784286A5052154004 @default.
• W4386784286 hasAuthorship W4386784286A5053307625 @default.
• W4386784286 hasAuthorship W4386784286A5060512446 @default.
• W4386784286 hasAuthorship W4386784286A5061365371 @default.
• W4386784286 hasAuthorship W4386784286A5071357841 @default.
• W4386784286 hasAuthorship W4386784286A5080716045 @default.
• W4386784286 hasAuthorship W4386784286A5087689377 @default.
• W4386784286 hasAuthorship W4386784286A5089200597 @default.
• W4386784286 hasConcept C121608353 @default.
• W4386784286 hasConcept C126322002 @default.
• W4386784286 hasConcept C143998085 @default.
• W4386784286 hasConcept C197934379 @default.
• W4386784286 hasConcept C203092338 @default.
• W4386784286 hasConcept C2777701055 @default.
• W4386784286 hasConcept C2777742743 @default.
• W4386784286 hasConcept C2779761222 @default.
• W4386784286 hasConcept C2779984678 @default.
• W4386784286 hasConcept C2780057760 @default.
• W4386784286 hasConcept C31760486 @default.
• W4386784286 hasConcept C526584372 @default.
• W4386784286 hasConcept C535046627 @default.
• W4386784286 hasConcept C71924100 @default.
• W4386784286 hasConceptScore W4386784286C121608353 @default.
• W4386784286 hasConceptScore W4386784286C126322002 @default.
• W4386784286 hasConceptScore W4386784286C143998085 @default.
• W4386784286 hasConceptScore W4386784286C197934379 @default.
• W4386784286 hasConceptScore W4386784286C203092338 @default.
• W4386784286 hasConceptScore W4386784286C2777701055 @default.
• W4386784286 hasConceptScore W4386784286C2777742743 @default.
• W4386784286 hasConceptScore W4386784286C2779761222 @default.
• W4386784286 hasConceptScore W4386784286C2779984678 @default.
• W4386784286 hasConceptScore W4386784286C2780057760 @default.
• W4386784286 hasConceptScore W4386784286C31760486 @default.
• W4386784286 hasConceptScore W4386784286C526584372 @default.
• W4386784286 hasConceptScore W4386784286C535046627 @default.
• W4386784286 hasConceptScore W4386784286C71924100 @default.
• W4386784286 hasIssue "18_Supplement" @default.
• W4386784286 hasLocation W43867842861 @default.
• W4386784286 hasOpenAccess W4386784286 @default.
• W4386784286 hasPrimaryLocation W43867842861 @default.
• W4386784286 hasRelatedWork W2947816590 @default.
• W4386784286 hasRelatedWork W3084285753 @default.
• W4386784286 hasRelatedWork W3177224496 @default.
• W4386784286 hasRelatedWork W4282964575 @default.
• W4386784286 hasRelatedWork W4362584161 @default.
• W4386784286 hasRelatedWork W4379280921 @default.
• W4386784286 hasRelatedWork W4379281327 @default.
• W4386784286 hasRelatedWork W4384922324 @default.
• W4386784286 hasRelatedWork W4385899003 @default.
• W4386784286 hasRelatedWork W4385899092 @default.
• W4386784286 hasVolume "29" @default.
• W4386784286 isParatext "false" @default.
• W4386784286 isRetracted "false" @default.
• W4386784286 workType "article" @default.